BL-1020

DRUG2 trials

Sponsors

BioLineRx, Ltd.

Conditions

Schizoaffective DisorderSchizophrenia

Phase 2

Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder

CompletedNCT00480571

BioLineRx, Ltd.Schizoaffective Disorder, Schizophrenia

Start: 2007-06-30End: 2007-12-31Target: 90Updated: 2009-07-21

Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

CompletedNCT00722176

BioLineRx, Ltd.Schizophrenia

Start: 2008-06-30End: 2009-12-31Target: 220Updated: 2010-06-29